🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

162 results for “Fondazione” Clear

  1. Sodio cloruro S.A.L.F. 0,9% solvente per uso parenterale., BCG 10 Anti-Tuberculosis Vaccine, Powder and solvent for suspension for intradermal injection Vaccinum tuberculosis (BCG) cryodesiccatum

    Fondazione Telethon ETS

    RIS (Radiologically Isolated Syndrome)

    phase 2 small molecule active

    1 trial

  2. Sodio ioduro (I131) Curium Netherlands 37-7400 MBq capsula rigida, -

    Fondazione Telethon ETS

    Metastatic DTC

    phase 2 small molecule active

    1 trial

  3. TEBENTAFUSP

    Fondazione Telethon ETS

    metastatic uveal melanoma HLA A*02:01 positive

    phase 2 small molecule active

    1 trial

  4. TECLISTAMAB, TECLISTAMAB

    Fondazione Telethon ETS

    refractory/relapsed multiple myeloma

    phase 2 small molecule active

    1 trial

  5. TEDOPI, LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  6. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial

  7. TEMOZOLOMIDE, TEMOZOLOMIDE, CAPECITABINE

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 small molecule active

    1 trial

  8. TEPADINA 15 mg powder for concentrate for solution for infusion, Trecondi 5 g powder for solution for infusion, Mozobil 20 mg/ml solution for injection, Trecondi 5 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Trecondi 1 g powder for solution for infusion, Autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded.

    Fondazione Telethon ETS

    Autosomal recessive osteopetrosis caused by mutations in the TCIRG1 gene

    phase 2 small molecule active

    1 trial

  9. TISLELIZUMAB

    Fondazione Telethon ETS

    Hodgkin lymphoma

    phase 2 small molecule active

    1 trial

  10. TOCILIZUMAB , CYCLOPHOSPHAMIDE , CD19-CAR_Lenti, FLUDARABINE , LEVETIRACETAM

    Fondazione Telethon ETS

    Refractory Systemic Autoimmune Diseases

    phase 2 small molecule active

    1 trial

  11. TOCILIZUMAB, OBINUTUZUMAB, GLOFITAMAB, GLOFITAMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  12. TRASTUZUMAB DERUXTECAN

    Fondazione Telethon ETS

    metastatic HER2-positive breast cancer patients

    phase 2 small molecule active

    1 trial

  13. TREMELIMUMAB, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, DURVALUMAB

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  14. Tasigna 150 mg hard capsules, Scemblix 40 mg film-coated tablets

    Fondazione Telethon ETS

    BCR-ABL1+ Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  15. Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  16. The Placebo composition is the same of the IMP except the active ingredient

    Fondazione Telethon ETS

    Optic Pathway Glioma (OPG)

    phase 2 small molecule active

    1 trial

  17. Ultravist 370 mg/ml soluzione iniettabile, OMNIPAQUE 350 mg I/ml soluzione iniettabile, VISIPAQUE 320 mg I/ml soluzione iniettabile

    Fondazione Telethon ETS

    breast pathology

    phase 2 small molecule active

    1 trial

  18. VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia with NPM1 mutation

    phase 2 small molecule active

    1 trial

  19. VINCRISTINE , MELPHALAN , DOXORUBICIN , CYCLOPHOSPHAMIDE , IFOSFAMIDE , Trecondi 1 g powder for solution for infusion, ETOPOSIDE , Trecondi 5 g powder for solution for infusion

    Fondazione Telethon ETS

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  20. VINORELBINE , GEMCITABINE, BENDAMUSTINE , ATEZOLIZUMAB , VINORELBINE TARTRATE, GEMCITABINE , BENDAMUSTINE HYDROCHLORIDE

    Fondazione Telethon ETS

    Hodgkin’s lymphoma

    phase 2 small molecule active

    1 trial

  21. VIZAMYL 400 MBq/mL solution for injection

    Fondazione Telethon ETS

    cardiac amyloidosis

    phase 2 small molecule active

    1 trial

  22. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  23. Vizimpro 15 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets

    Fondazione Telethon ETS

    Advanced or metastatic untreated EGFR mutation positive NSCLC

    phase 2 small molecule active

    1 trial

  24. Xospata 40 mg film-coated tablets

    Fondazione Telethon ETS

    newly diagnosed non-M3 FLT3-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources